Tryptanthrin exerts anti-breast cancer effects both in vitro and in vivo through modulating the inflammatory tumor microenvironment

被引:38
|
作者
Zeng, Qingfang [1 ,2 ]
Luo, Cairong [1 ,2 ]
Cho, Junlae [3 ]
Lai, Donna [3 ]
Shen, Xiangchun [1 ]
Zhang, Xiaoyan [1 ,2 ]
Zhou, Wei [1 ]
机构
[1] Guizhou Med Univ, Sch Pharm, Key Lab Optimal Utilizaiton Nat Med Resources, Guiyang 550025, Guizhou, Peoples R China
[2] Guizhou Med Univ, Sch Basic Med Sci, Guiyang 550025, Guizhou, Peoples R China
[3] Univ Sydney, Fac Med & Life Sci, Sydney, NSW 2006, Australia
关键词
tryptanthrin; antitumor; inflammatory tumor microenvironment; epithelial-mesenchymal transition; natural medicine; CELLS; INTERLEUKIN-2; CYTOTOXICITY; PERSPECTIVES; APOPTOSIS; PATHWAYS;
D O I
10.2478/acph-2021-0020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tryptanthrin is an indole quinazoline alkaloid from the indigo-bearing plants, such as Isatis indigotica Fort. Typically, this natural compound shows a variety of pharmacological activities such as antitumor, antibacterial, anti-inflammatory and antioxidant effects. This study was conducted to assess the antitumor activity of tryptanthrin in breast cancer models both in vitro and in vivo, and to explore the important role of the inflammatory tumor microenvironment (TME) in the antitumor effects of tryptanthrin. Human breast adenocarcinoma MCF-7 cells were used to assess the antitumor effect of tryptanthrin in vitro. MTT assay and colony formation assay were carried out to monitor the antiproliferative effect of tryptanthrin (1.56-50.0 mu mol L-1) on inhibiting the proliferation and colony formation of MCF-7 cells, respectively. The migration and invasion of MCF-7 cells were evaluated by wound healing assay and Transwell chamber assay, respectively. Moreover, the 4T1 murine breast cancer model was established to examine the pharmacological activity of tryptanthrin, and three groups with different doses of tryptanthrin (25, 50 and 100 mg kg(-1)) were set in study. Additionally, tumor volumes and organ coefficients were measured and calculated. After two weeks of tryptanthrin treatment, samples from serum, tumor tissue and different organs from tumor-bearing mice were collected, and the enzyme-linked immunosorbent assay (ELISA) was performed to assess the regulation of inflammatory molecules in mouse serum. Additionally, pathological examinations of tumor tissues and organs from mice were evaluated through hematoxylin and eosin (H&E) staining. The expression of inflammatory proteins in tumor tissues was measured by immunohistochemistry (IHC) and Western blotting. Tryptanthrin inhibited the proliferation, migration and invasion of MCF-7 cells, up-regulated the protein level of E-cadherin, and down-regulated those of MMP-2 and Snail, as suggested by the MCF-7 cell experiment. According to the results from in vivo experiment, tryptanthrin was effective in inhibiting tumor growth, and it showed favorable safety without inducing the fluctuations of body mass and organ coefficient ( p > 0.05). In addition, tryptanthrin also suppressed the expression levels of NOS1, COX-2 and NF-kappa B in mouse tumor tissues, and regulated those of IL-2, IL-10 and TNF-alpha in the serum of tumor cells-transplanted mice. Tryptanthrin exerted its anti-breast cancer activities through modulating the inflammatory TME both in vitro and in vivo.
引用
收藏
页码:245 / 266
页数:22
相关论文
共 50 条
  • [11] SP-8356, a (1S)-(–)-verbenone derivative, exerts in vitro and in vivo anti-breast cancer effects by inhibiting NF-κB signaling
    Sunam Mander
    Dong Hwi Kim
    Huong Thi Nguyen
    Hyo Jeong Yong
    Kisoo Pahk
    Eun-Yeong Kim
    Kiho Lee
    Jae Young Seong
    Won-Ki Kim
    Jong-Ik Hwang
    Scientific Reports, 9
  • [12] A pyrazolopyridine as a novel AhR signaling activator with anti-breast cancer properties in vitro and in vivo
    Abduh, Maisa S.
    Alwassil, Osama I.
    Aldaqal, Saleh M.
    Alfwuaires, Manal A.
    Farhan, Mahdi
    Hanieh, Hamza
    BIOCHEMICAL PHARMACOLOGY, 2024, 222
  • [13] Phytoestrogen Bakuchiol Exhibits In Vitro and In Vivo Anti-breast Cancer Effects by Inducing S Phase Arrest and Apoptosis
    Li, Li
    Chen, Xueping
    Liu, Chi C.
    Lee, Lai S.
    Man, Cornelia
    Cheng, Shuk H.
    FRONTIERS IN PHARMACOLOGY, 2016, 7
  • [14] VISTA deficiency exerts anti-tumor effects in breast cancer through regulating macrophage polarization
    Jin, Shasha
    Liu, Wanmei
    He, Xiaoyu
    Zhang, Yuxin
    Chen, Wenting
    Wu, Yinhao
    Liu, Jun
    Barber, Amorette
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 136
  • [15] In vitro anti-breast cancer studies of LED red light therapy through autophagy
    Yang, Kok Lee
    Khoo, Boon Yin
    Ong, Ming Thong
    Yoong, Ivan Chew Ken
    Sreeramanan, Subramaniam
    BREAST CANCER, 2021, 28 (01) : 60 - 66
  • [16] In vitro anti-breast cancer studies of LED red light therapy through autophagy
    Kok Lee Yang
    Boon Yin Khoo
    Ming Thong Ong
    Ivan Chew Ken Yoong
    Subramaniam Sreeramanan
    Breast Cancer, 2021, 28 (1) : 60 - 66
  • [17] Synthesis, In Vitro, and In Vivo Investigations of Pterostilbene-Tethered Analogues as Anti-Breast Cancer Candidates
    Li, Guoxun
    Li, Jian
    Wang, Wenqian
    Feng, Xiaoqing
    Yu, Xingkang
    Yuan, Shuo
    Zhang, Wei
    Chen, Jialing
    Hu, Caijuan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
  • [18] In vitro and in vivo studies of a decanuclear Ni(II) complex as a potential anti-breast cancer agent
    Zhu, Haitao
    Li, Houcong
    Ji, Yuxin
    Hou, Min
    Yang, Qingling
    Liang, Lili
    Li, Wenge
    BIOORGANIC CHEMISTRY, 2024, 153
  • [19] Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
    Wang, Fei
    Yuan, Chong
    Liu, Bo
    Yang, Yan-Fang
    Wu, He-Zhen
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [20] IL-9 Exerts Antitumor Effects in Colon Cancer and Transforms the Tumor Microenvironment In Vivo
    Wang, Jin
    Sun, Mingbing
    Zhao, Hua
    Huang, Yang
    Li, Dongbao
    Mao, Deli
    Zhang, Zhe
    Zhu, Xinguo
    Dong, Xiaoqiang
    Zhao, Xin
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2019, 18